~~<i id='10B88D9949'><strike id='10B88D9949'><tt id='10B88D9949'><pre id='10B88D9949'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

explore

focus

author：explore 2025-09-29 17:52:40 - browse：5447

Eli Lilly said Friday that it will acquire Dermira, a small biotech developing drugs for chronic skin conditions, for $1.1 billion.

The centerpiece of the deal is the Dermira drug called lebrikizumab that aims to treat people suffering from moderate-to-severe atopic dermatitis, the most common form of eczema, a disease characterized by inflamed, itchy, and scaly skin.

Phase 3 clinical trials of lebrikizumab in atopic dermatitis are underway. If successful, the drug could compete against Dupixent, which has grown into a commercial blockbuster for Regeneron Pharmaceuticals and Sanofi.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： Male and female sex labels in research insufficient, scientists say

leisure time

Wikipedia

leisure time

hotspot

AdobeCHICAGO—Peoplecanbemightilyreluctanttogetacolonoscopyforreasonslikecost,languagebarriers,orfear

WSS

Boston's new lab space is opening empty

How many hemophilia patients actually want gene therapy?

FDA advisers back CAR

Shifting the focus from loneliness to social health

John Green on his newest strategy for fighting tuberculosis

Boston's new lab space is opening empty

explore

focus

leisure time

Moonlake's readout produced a cash windfall. Risks remain

R.J. Reynolds sues to protect 'crisp' cigs from California flavor ban

Wildfire smoke exposes gaps in outdoor worker protections

ASCO: AstraZeneca's hat trick, and palliative care's spotlight

Medicare details structure of new drug price negotiation program

FDA advisers back CAR

State Dept. review finds Biden bears some blame for Afghanistan failures

Steward Health Care Massachusetts hospitals face fiscal disaster

Hollywood unions extend contract negotiations for actors

At ASCO, AstraZeneca reports strong data for breast cancer drug

Wikipedia

Medicare coverage of Wegovy, once blocked, now looks possible

Male and female sex labels in research insufficient, scientists say

ASCO 2024: 'Reassuring' Corbus data on ADC bladder cancer drug

How to increase colonoscopy rates? Looks like an AI can help

HIV drugs protect against transmission, even in unprotected sex

First U.S. drug developed to treat liver disease MASH is approved

leisure time

hotspot

hotspot

hotspot